One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
Completed · Early Phase 1
Conditions studied: Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
In brief
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, that can be given safely over one week. The investigators plan to infuse low doses of intravenous PTHrP to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrp on markers of bone turnover, and plasma 1,25 (OH)2 vitamin D regulation in healthy human volunteers.
Key facts
- Study ID
- NCT00580788
- Run by
- University of Pittsburgh
- People needed
- 14
- Starts
- 2008-01-01
- Expected to finish
- 2009-12-01
- Last updated by the study team
- 2016-02-11
Who can join
Age: 24 and older, up to 35. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy caucasian subjects of both sexes between the ages of 24-35 years, who are able to spend one week on the Clinical \& Translational Research Center at the University of Pittsburgh Medical Center (UPMC) Montefiore
You may not qualify if…
- Pregnancy
- Any cardiac, renal, pulmonary, endocrine, musculoskeletal, hepatic, hematological, malignant or rheumatologic diseases
- Body mass index great than 30
- Anemia
- Significant alcohol or drug abuse
- Baseline hypotension or hypertension
- Abnormal screening labs
- Use of certain chronic medications excluding oral contraceptives
- Receiving an investigational drug in the last 90 days
- Previously receiving PTH or PTHrP
- African-American race
Where it is running
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.